Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies, Inc. (PTNT)
:PTNT
PTNT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.77 - $72.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.50K
Market Cap
$8.95M
Enterprise Value$13.10M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Oct 07, 2025EPS Estimate
-9.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.00
Shares Outstanding973,341
10 Day Avg. Volume3,278
30 Day Avg. Volume5,497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Palatin Technologies News
PTNT FAQ
What was Palatin Technologies, Inc.’s price range in the past 12 months?
Palatin Technologies, Inc. lowest stock price was $1.77 and its highest was $72.50 in the past 12 months.
What is Palatin Technologies, Inc.’s market cap?
Palatin Technologies, Inc.’s market cap is $8.95M.
When is Palatin Technologies, Inc.’s upcoming earnings report date?
Palatin Technologies, Inc.’s upcoming earnings report date is Oct 07, 2025 which is in 12 days.
How were Palatin Technologies, Inc.’s earnings last quarter?
Palatin Technologies, Inc. released its earnings results on May 14, 2025. The company reported -$9 earnings per share for the quarter, missing the consensus estimate of -$8.5 by -$0.5.
Is Palatin Technologies, Inc. overvalued?
According to Wall Street analysts Palatin Technologies, Inc.’s price is currently Overvalued.
Does Palatin Technologies, Inc. pay dividends?
Palatin Technologies, Inc. does not currently pay dividends.
What is Palatin Technologies, Inc.’s EPS estimate?
Palatin Technologies, Inc.’s EPS estimate is -9.5.
How many shares outstanding does Palatin Technologies, Inc. have?
Palatin Technologies, Inc. has 973,341 shares outstanding.
What happened to Palatin Technologies, Inc.’s price movement after its last earnings report?
Palatin Technologies, Inc. reported an EPS of -$9 in its last earnings report, missing expectations of -$8.5. Following the earnings report the stock price went up 14.88%.
Which hedge fund is a major shareholder of Palatin Technologies, Inc.?
Currently, no hedge funds are holding shares in PTNT
Company Description
Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
PTNT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with significant achievements in reducing net loss and promising clinical trial results. However, challenges remain with the absence of product sales and a decrease in cash position. The company is actively pursuing strategic partnerships to enhance its future prospects.View all PTNT earnings summariesTechnical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―